{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:54:43Z","timestamp":1783436083238,"version":"3.54.6"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Xylazine in an anesthetic drug used for the sedation of animals and increasingly appearing as an adulterant in uncontrolled drug supplies, primarily illicit fentanyl. The ability to detect xylazine exposure by urine drug testing may improve monitoring of this drug trend and our understanding of the effects and risks associated with xylazine exposure. Currently, limited information is available regarding the elimination of xylazine or its metabolites in humans. In this study, we report quantification of xylazine and 4-hydroxy-xylazine (4-OH-x) in hydrolyzed urine specimens collected from 109 patients testing positive for fentanyl and xylazine using liquid chromatography tandem mass spectrometry (LC-MS\/MS). 4-hydroxy-xylazine was a minor urinary metabolite in most patients with a median metabolite-to-xylazine (MR) concentration ratio 0.09. Additional urinary metabolites were identified including oxo-xylazine (oxo-x), OH-oxo-xylazine (OH-oxo-x), OH-sulfone-xylazine (OH-sulfone-x), and sulfone-xylazine (sulfone-x), with median MR peak area ratios of &amp;lt;\u20090.01, 0.60, 0.30, and 1.60, respectively. Sulfone-x signal exceeded that of xylazine in more than 70% of urine specimens. Sulfone-x is not glucuronidated and does not appear to form positional isomers. Additional studies are needed to examine whether detection of xylazine metabolites may improve the sensitivity and\/or extend the detection time window for xylazine exposure.<\/jats:p>","DOI":"10.1093\/jat\/bkaf078","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:52:42Z","timestamp":1755085962000},"source":"Crossref","is-referenced-by-count":3,"title":["Xylazine and major urinary metabolites detected in patients positive for fentanyl and xylazine"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-9495","authenticated-orcid":false,"given":"Yanchun","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pathology & Immunology, Washington University School of Medicine , St Louis, MO 63110,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3535-6707","authenticated-orcid":false,"given":"Bridgit O","family":"Crews","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University School of Medicine , St Louis, MO 63110,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2026041500165483700_bkaf078-B1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Giovannitti","year":"2015","journal-title":"Anesth Prog"},{"key":"2026041500165483700_bkaf078-B2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drugalcdep.2008.03.005","article-title":"GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles","volume":"96","author":"Rodr\u00edguez","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"2026041500165483700_bkaf078-B3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1556-4029.2007.00648.x","article-title":"Concurrent detection of heroin, fentanyl, and xylazine in seven drug-related deaths reported from the Philadelphia Medical Examiner\u2019s Office","volume":"53","author":"Wong","year":"2008","journal-title":"J Forensic Sci"},{"key":"2026041500165483700_bkaf078-B4","doi-asserted-by":"crossref","first-page":"e2350630","DOI":"10.1001\/jamanetworkopen.2023.50630","article-title":"Xylazine in overdose deaths and forensic drug reports in US States, 2019-2022","volume":"7","author":"Cano","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026041500165483700_bkaf078-B5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl\u2013involved overdose deaths with detected xylazine\u2013United States, January 2019\u2013June 2022","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026041500165483700_bkaf078-B6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","article-title":"The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico","volume":"89","author":"Reyes","year":"2012","journal-title":"J Urban Health"},{"key":"2026041500165483700_bkaf078-B7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/ADM.0000000000001245","article-title":"Xylazine-associated wounds: clinical experience from a low-barrier wound care clinic in Philadelphia","volume":"18","author":"McFadden","year":"2024","journal-title":"J Addict Med"},{"key":"2026041500165483700_bkaf078-B8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/ADM.0000000000001396","article-title":"Xylazine positivity in opioid-positive drug screens on an inpatient labor unit","volume":"19","author":"Trammel","year":"2025","journal-title":"J Addict Med"},{"key":"2026041500165483700_bkaf078-B9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/clinchem\/hvae163","article-title":"Xylazine pharmacokinetics in patients testing positive for fentanyl and xylazine","volume":"71","author":"Lin","year":"2025","journal-title":"Clin Chem"},{"key":"2026041500165483700_bkaf078-B10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0090-9556(25)08804-X","article-title":"Characterization of metabolites of xylazine produced in vivo and in vitro by LC\/MS\/MS and by GC\/MS","volume":"20","author":"Mutlib","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"2026041500165483700_bkaf078-B11","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1007\/s00216-013-7419-7","article-title":"Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC\u2013MS, LC\u2013MSn, and LC\u2013HR-MSn","volume":"405","author":"Meyer","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"2026041500165483700_bkaf078-B12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/jat\/bkae043","article-title":"Evaluation of the ARK diagnostics immunoassay for qualitative detection of xylazine in urine","volume":"48","author":"Kyle","year":"2024","journal-title":"J Anal Toxicol"},{"key":"2026041500165483700_bkaf078-B13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1515\/cclm-2024-0947","article-title":"Clinical performance of a new lateral flow immunoassay for xylazine detection","volume":"63","author":"Contella","year":"2025","journal-title":"Clin Chem Lab Med"},{"key":"2026041500165483700_bkaf078-B14","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/ajcp\/aqae129.354","article-title":"Quantitation and abundance of xylazine and xylazine metabolites in human urine and plasma by LC-MS\/MS","volume":"162","author":"Lin","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"2026041500165483700_bkaf078-B15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/jalm\/jfae158","article-title":"The prevalence of xylazine in patient urine samples that were positive for fentanyl in Western New York","volume":"10","author":"Young","year":"2025","journal-title":"J Appl Lab Med"},{"key":"2026041500165483700_bkaf078-B16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/jat\/bkz115","article-title":"ANSI\/ASB standard 036 for method validation in forensic toxicology has replaced SWGTOX\u2019s version","volume":"44","author":"LeBeau","year":"2020","journal-title":"J Anal Toxicol"},{"key":"2026041500165483700_bkaf078-B17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jat\/bkt054","article-title":"Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology","volume":"37","year":"2013","journal-title":"J Anal Toxicol"},{"key":"2026041500165483700_bkaf078-B18","volume-title":"Liquid Chromatography-Mass Spectrometry Methods","author":"C62Ed2","edition":"2nd edn"},{"key":"2026041500165483700_bkaf078-B19","doi-asserted-by":"crossref","first-page":"108300","DOI":"10.1016\/j.drugalcdep.2020.108300","article-title":"Drug checking identifies counterfeit alprazolam tablets","volume":"218","author":"Tobias","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2026041500165483700_bkaf078-B20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bmc.2875","article-title":"Characterization of xylazine metabolism in rat liver microsomes using liquid chromatography\u2013hybrid triple quadrupole\u2013linear ion trap\u2013mass spectrometry","volume":"27","author":"Lavoie","year":"2013","journal-title":"Biomed Chromatogr"},{"key":"2026041500165483700_bkaf078-B21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ajcp\/aqae129.358","article-title":"A quantitative LC-MS\/MS method for xylazine and metabolites in urine","volume":"162","author":"Orahoske","year":"2024","journal-title":"Am J Clin Path"},{"key":"2026041500165483700_bkaf078-B22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/ADM.0000000000001513","article-title":"Development and validation of a high-sensitivity rapid xylazine dipstick for clinical urine testing","volume":"19","author":"Wang","year":"2025","journal-title":"J Addict Med"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaf078\/64046051\/bkaf078.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/1\/bkaf078\/64046051\/bkaf078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/1\/bkaf078\/64046051\/bkaf078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:17:05Z","timestamp":1776226625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/doi\/10.1093\/jat\/bkaf078\/8234520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaf078","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,8,14]]},"article-number":"bkaf078"}}